A Democratic lawmaker raised new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs, including whether senior officials involved in the effort are complying with federal ethics rules.
In a letter sent Tuesday, Rep. Jake Auchincloss of Massachusetts took issue with the lack of transparency in FDA's handling of the program and questioned its legal underpinnings, noting that Congress did not sign off on the plan.
